- Acer Therapeutics Inc (NASDAQ:ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.
- The study showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801’s ability to decrease the frequency or severity of hot flashes in postmenopausal women.
- Related: Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder.
- Hence, Acer is pausing the ACER-801 program until Acer has thoroughly reviewed the full data set.
- Acer is continuing to focus on preparation for its commercial launch of OLPRUVA (sodium phenylbutyrate) for urea cycle disorders and the ongoing Phase 3 trial of EDSIVO (celiprolol) for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, subject to availability of additional capital beyond early in Q2 2023.
- In December 2018, Acer entered into an exclusive license agreement with Sanofi SA (NASDAQ:SNY) to acquire worldwide rights to ACER-801 (osanetant).
- Price Action: ACER shares are down 39.96% at $0.9306 on the last check Friday.
Why This Twitter Analyst Is Raising The Stock’s Price Target
Twitter Inc (NYSE: TWTR) shares are up more than 18% over the opening price on Monday on news that Tesla Inc (NASDAQ:
